newsfilter
← Latest News
ACCESS Newswire·

Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, AUGUST 4, 2022 AT 8:00 AM EDT Adjustments to PRS-060/AZD1402 phase 2 study design boost enrollment rate and facilitate a topline readout by 3Q23 Cinrebafusp alfa (PRS-343) demonstrating clinical